MFAT (micro-fragmented adipose tissue, harvested from your own fat) and BMA (bone marrow aspirate, drawn from your own pelvis) are the two autologous stem cell sources used in regenerative orthopedics, and neither is universally better. They are alternatives, never combined into one injection. The right source is a physician decision made for your specific joint from imaging, your age and body composition, the stage of arthritis, and prior procedures, not whichever source a clinic happens to stock. At Dynamic Athlete in Boulder, Colorado, Aneesh Garg, DO, CAQ selects the source, then co-delivers it with High-Dose PRP and Exosome-Containing Fibrin-Rich Plasma under live ultrasound as the Dynamic Stem Cell+ protocol. If you searched MFAT vs BMA, you want to know which one is right for you. The honest answer is that the choice itself is the medicine.
MFAT and BMA, compared
Two sources of your own regenerative tissue, two harvest sites, one decision.
| MFAT | BMA | |
|---|---|---|
| What it is | Micro-fragmented adipose tissue | Bone marrow aspirate |
| Harvest site | Your own fat, a small mini-liposuction step | Your own iliac crest (pelvis) |
| Cell profile | A dense structural scaffold from fat, rich in pericytes and stromal vascular fraction | A marrow-derived population of mesenchymal signaling cells plus growth factors |
| Often chosen for | A more degenerated joint that tolerates the adipose environment well | Cases where a marrow-derived population, with its chondrogenic profile, is the better match |
| Co-delivered with | High-Dose PRP and Fibrin-Rich Plasma | High-Dose PRP and Fibrin-Rich Plasma |
What is the same, and what differs
Both are autologous, same-day, minimally manipulated procedures: your own tissue, harvested and returned in one visit, not a donor vial and not a manufactured drug. Neither uses embryonic cells, and neither is an amniotic or umbilical cord product, which is a different category that may not contain living cells. What differs is the harvest and the cell profile. Adipose tissue is a comparatively rich, easily harvested source of regenerative and structural cells, delivering a dense scaffold that tolerates a degenerated joint well. Bone marrow supplies a marrow-derived cell population often cited for its chondrogenic potential, along with signaling growth factors. Neither is a default, and no honest clinic can promise an outcome from either.
Why the choice is the medicine
The variable that decides your result is not which source is fashionable. It is whether a physician matched the source to your joint, and whether it was paired and placed correctly.
The source is selected from your imaging, not from a menu
Dr. Garg weighs the stage of arthritis on your imaging, the joint being treated, your age and body composition, prior procedures, and your goals, then names MFAT or BMA. The published evidence supports both for knee osteoarthritis: a 2019 comparison in Stem Cells Translational Medicine (Mautner et al.) found micro-fragmented adipose tissue and bone marrow aspirate concentrate produced comparable functional improvement, with no significant difference between the two sources. The evidence base is encouraging but still maturing, so with both supported the decision belongs to the joint in front of you, not to whichever source a clinic stocks.
Whichever source, it is never injected alone
Neither MFAT nor BMA goes in bare. The selected source is always co-delivered with High-Dose PRP, platelets concentrated 12 to 20 times baseline (over 10 billion) versus the 2 to 3 times most clinics produce, plus Exosome-Containing Fibrin-Rich Plasma. The platelets and fibrin are the signaling and scaffolding environment around the cells, and the fibrin matrix helps keep the material at the target. The pairing that matters is source plus High-Dose PRP, not MFAT plus BMA.
The physician who chooses the source also performs it
Stem cell therapy is image-guided medicine, not a commodity injection. The harvest, the preparation, and the placement each carry judgment. Every Dynamic Stem Cell+ procedure is performed by Aneesh Garg, DO, CAQ, from source selection through live ultrasound delivery, never a technician. He is regenerative-medicine teaching faculty at the Regenerative Medicine Training Institute and Rocky Vista University, the physician who teaches this work to other physicians. You can read the full method in our complete guide to stem cell therapy, or see the treatment overview on our stem cell therapy page.
Print this before you choose a source
Three questions separate a physician-selected source from a single product sold under the stem cell label. Ask all three before you book, so you can tell the difference for yourself.
- Do you offer both MFAT and BMA, and does a physician select the source for my joint? A clinic that stocks one source recommends that source to everyone.
- Is this my own tissue, MFAT or BMA, rather than a donor vial? An amniotic or umbilical cord product is a different category that may not contain living cells.
- Who performs it, and is it placed under live ultrasound? “The physician, under live ultrasound” and “High-Dose PRP at 12 to 20 times baseline” are the answers you want.
Frequently asked questions
What is the difference between MFAT and BMA?
MFAT and BMA are two sources of your own regenerative tissue, and they are alternatives, not a combination. MFAT (micro-fragmented adipose tissue) is harvested from your own fat through a mini-liposuction step, then mechanically processed into small fragments without enzymes; fat is a dense source of regenerative and structural cells, rich in pericytes and stromal vascular fraction, and it tolerates a degenerated joint environment well. BMA (bone marrow aspirate) is drawn from your own iliac crest, the pelvis, and supplies a marrow-derived population of mesenchymal signaling cells along with growth factors. Both are autologous, same-day, minimally manipulated procedures, not donor vials and not manufactured drugs. The difference that matters is not which acronym sounds stronger; it is which source matches your joint, which is why the choice should be a physician decision.
Is MFAT or BMA better for knee osteoarthritis?
Neither is universally better; the right source depends on the joint, the pathology, and the patient, which is exactly why source selection should be a physician decision rather than whatever a clinic stocks. A 2019 head-to-head comparison in Stem Cells Translational Medicine (Mautner et al.) found micro-fragmented adipose tissue and bone marrow aspirate concentrate produced comparable functional improvement in symptomatic knee osteoarthritis, with no significant difference between them. Prospective studies and systematic reviews of both sources report improvement in pain and function for many patients, though trials vary in technique and dose and the evidence is still maturing. There is no guaranteed result, and any clinic that promises one should be a warning sign. In our Dynamic Stem Cell+ protocol, over 90% of our patients self-report a 75% or greater improvement, all without surgery. That figure is self-reported, not a guarantee, and candidacy is assessed individually.
How does a physician decide between MFAT and BMA?
The decision is made for your specific joint, from imaging and history, not from a menu. Dr. Garg weighs the stage of arthritis on your imaging, your age and body composition, the joint being treated, prior procedures, and your goals. For a more degenerated joint, fat often tolerates the environment well, so MFAT is frequently the source chosen; for other joints and patients, a marrow-derived population from BMA may be the better match. Body composition matters too: there must be enough harvestable fat for MFAT, while BMA depends on a healthy marrow draw. This is why the source should be named after the evaluation, not before, and why the same practice offers both rather than selling one to everyone.
Can MFAT and BMA be combined in one procedure?
At Dynamic Athlete, MFAT and BMA are treated as alternatives, not combined into a single injection. They are two routes to the same goal, your own regenerative tissue placed in the joint, and the medicine is choosing the right route for your case rather than stacking both. What is always combined is the supporting biologic environment: whichever source is selected, it is co-delivered with High-Dose PRP, platelets concentrated 12 to 20 times baseline, over 10 billion, plus Exosome-Containing Fibrin-Rich Plasma. The platelets and fibrin act as the signaling and scaffolding environment around the cells, and the fibrin matrix helps keep the material where it is placed. So the pairing that matters is source plus High-Dose PRP, under live ultrasound, not MFAT plus BMA.
What should I ask a Boulder clinic before choosing a stem cell source?
Ask three direct questions before booking stem cell therapy at any Boulder clinic, so you can compare answers directly. First, do you offer both MFAT and BMA, and does a physician select the source for my specific joint, or do you only stock one option? A clinic that owns one source will recommend that source to everyone. Second, is this my own tissue, MFAT or BMA, rather than an amniotic or umbilical cord vial, which is a different category that may not contain living cells? Third, who performs the procedure and how is it placed, by the physician under live ultrasound, or by feel? At Dynamic Athlete, both sources are available, the source is selected by Aneesh Garg, DO, CAQ from your imaging, and the entire Dynamic Stem Cell+ procedure is performed by him under live ultrasound, never a technician.
To find out whether MFAT or BMA is the right source for your joint, book an evaluation with Aneesh Garg, DO, CAQ. Every plan starts with imaging-based staging, an honest candidacy assessment, and a source matched to your joint, then delivered as Dynamic Stem Cell+ under live ultrasound.